P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

Breaking News

P&T TV

Phase 2 Study of Intralesional PV-10 (Rose Bengal) in Metastatic Melanoma

Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology at St. Luke’s University Health Network in Bethlehem, PA, and Professor of Medicine at Temple University in Philadelphia, PA, discusses several scenarios in which PV-10 might be used if it is ultimately approved for patients with advanced melanoma.

2013 European Cancer Congress

P&T Community

Update Your Registration Profile

Haven't received your weekly newsletters about the new features on PTcommunity.com? Check your newsletter status by clicking here. Scroll down to the question, 'Check here if you would like to receive our e-newsletter?' and choose 'Yes' or 'No.'

Having trouble with the site? Send an email.

Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.

P&T Journal
for April 2014

Features

Evaluation of Discharge Medication Orders Following Automatic Therapeutic Substitution of Commonly Exchanged Drug Classes

The Pharmaceutical Industry Tussles Over Biosimilars

Q&A

Carlos Fernández-del Castillo Confronts the Challenge of Pancreatic Cancer

Viewpoint

Hypertension: Is It Time to Replace Drugs with Nutrition and Nutraceuticals?

Departments

Medication Errors

Affirmative Warnings (Do This) May Be Better Understood Than Negative Warnings (Do Not Do That)

Prescription: Washington

Federal Investigative Report Questions 340B Contract Pharmacy Programs

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update

Drug Forecast

Suvorexant, a Dual Orexin Receptor Antagonist for the Management of Insomnia

About P&T

Contacts:

Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

David B. Nash, MD, MBA, editor-in-chief of P&T, is Dean of the Jefferson School of Population Health, Philadelphia. From 1996 to 2003, he served as the first Associate Dean for Health Policy at Jefferson Medical College. In 2004, he was named Co-director of the Masters Program in Public Health at Jefferson.

View the rest of the Editorial Board here.

Call For Papers

P&T Journal is now accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please see our author guidelines below or contact the editor, Sonja Sherritze, via phone 267-685-2779 or email: ssherritze@medimedia.com.

Guidelines For Authors

Subscribe to P&T

Print Edition

Resources

Clinical Briefs

Pharmacy Policies/Procedures: Forms and guidelines

Cost Calculators: Exclusive online tools to evaluate your pharmacy costs

Links: A comprehensive map of web links to the world of managed care pharmacy

Formulary Kits

Abilify Maintena™
(aripiprazole) for extended-release injectable suspension

Please click for FULL PRESCRIBING INFORMATION including Boxed WARNING

DUAVEE™
(Conjugated Estrogens/ Bazedoxifene)

ELIQUIS®
(apixaban) tablets

Please click for FULL PRESCRIBING INFORMATION including Boxed WARNINGS

GRANIX™
(tbo-filgrastim) Injection

Injectafer®
(ferric carboxymaltose injection)

INVOKANA™
(canagliflozin)

JAKAFI®
(ruxolitinib)

Quillivant XR™
(methylphenidate HCl) for extended-release oral suspension, CII

Please click for FULL PRESCRIBING INFORMATION, including Boxed WARNING

Simponi®
(golimumab)

SIMPONI® ARIA™
(golimumab) for infusion

Recent Headlines